about
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysisAnti-thrombotic therapy of acute coronary syndromes without ST elevationA randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing NecroImpact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study.Composition of coronary thrombus in acute myocardial infarction.High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data.Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Rapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion.Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms.Transradial versus transfemoral approach for percutaneous coronary intervention in cardiogenic shock: A radial-first centre experience and meta-analysis of published studies.Part 5: Acute Coronary Syndromes: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI.Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis.Impact of transfer time on mortality in acute coronary syndrome with ST-segment elevation treated by angioplasty.Antecubital vs Femoral Venous Access for Right Heart Catheterization: Benefits of a Flashback.Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial.New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates.Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.Slow response to clopidogrel predicts low response.Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease.Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction.Switching acute coronary syndrome patients from prasugrel to clopidogrel.Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors.Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis.Can we override clopidogrel resistance?Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia.Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis.Feasibility of outpatient coronary angiography with "ad hoc" angioplasty.Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
P50
Q22242057-B3BB7734-9823-4BB4-9178-099AD6EA4E46Q28188639-3F0111AC-3B80-4430-809A-CF4F981A4B3FQ28200405-EFE2AE02-4607-454F-9101-A08733A42092Q33622182-88EF9588-85B8-4087-AD96-A2186FEDA8D5Q33849557-E0BEF686-FB7B-4D89-9129-200768CF43ABQ33879249-9AAB2909-2865-4657-9CA2-0EBF09D3EF66Q34044204-1A27974D-CB19-4DD3-9A4E-5F1748E7645DQ34910745-1AD0B6DC-1BDE-435F-9234-3BADD2ED4BC9Q35000773-DB94DA2E-BDB6-4FDC-AA35-B16AD24133BBQ35204942-246933A6-818A-493A-892B-6A7EFDEE6467Q35722993-8399ED6C-A38C-4C2C-8945-F446AA5795B4Q37396406-1B24845E-2219-4893-B54A-3D2D27415E6BQ38040078-38181C38-AA4D-4115-A4F3-3E44A0341544Q38071527-7379899B-9A57-4F40-B65C-543380429AD7Q38432477-134804B9-3E05-4527-82F4-49AED1E62F26Q38542681-307B6660-7EBB-4844-B3F9-5CA60EF313E2Q38586073-42765909-9045-434C-A728-55F21ECC9109Q38608767-A0F8A661-C1D5-4959-BF12-34E0D17E1E75Q38701943-80E51392-45A8-4567-809A-8E543E8D225DQ38961670-8ADD790A-6366-4037-8ECD-2E22104835B2Q39693579-899ED86C-BFA0-4A1A-B8E2-65D28BFD04C3Q40077810-7E9380C8-23AD-4901-95DE-06F1275FDDCBQ40639563-67826DAC-6530-454B-B8E1-A0D265DD85C3Q40787167-D109EE7C-A1CA-467B-9775-0C9FD690A93DQ42863647-22189E6B-E29C-4FAE-B0F8-3F84520A5236Q42923877-BD29706D-816E-4749-8944-122B80316649Q42932241-31F4A053-700F-4A40-8118-BE854A0F678AQ42974062-B472F6C1-7440-442F-B6AB-F435A818518DQ43156263-8AD693E2-1F7C-4250-A04E-FDB9D2C0C770Q43156282-AD2A49AD-C8BC-4E0D-96AA-0E65890E069EQ43259572-38EA5BD5-D9F9-4A81-B3D5-6D53BC797BA7Q43274109-36B94541-1449-46B3-983E-64269277532CQ43685527-FAF7F3CE-66A6-4B83-9087-9FB2DC520BBCQ44423871-6B49DE63-B4CE-4E2F-853B-B95D52DAE304Q44453239-B9CBF0B8-7964-4C05-875B-9CF7C706B0A3Q45987163-DB7F7221-0EC6-4C50-997F-4265CF51E8FCQ46096530-8C0452BA-6FD5-4298-A112-0513B28C064AQ46218840-2073452C-D817-4D02-93A6-32EBE0EEF425Q46353090-8614A3E0-45D6-41F6-BCBA-5E9F0CAEF8BEQ46395652-D18F97FC-2A38-46EE-9EB6-EF7870305BF8
P50
name
Farzin Beygui
@en
Farzin Beygui
@nl
type
label
Farzin Beygui
@en
Farzin Beygui
@nl
prefLabel
Farzin Beygui
@en
Farzin Beygui
@nl